Species differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirus.
Clinically relevant doses of helper-dependent adenoviruses (HDAds) provoke the host response against capsid proteins in primates and rodents. To determine if PEGylation truly affects this, baboons and mice were given either HDAd or PEG-HDAd expressing beta-galactosidase at 5 × 10¹¹ or 3 × 10¹² virus particles per kilogram (vp/kg) by iv infusion. Serum cytokines and blood chemistries were assessed for 96 h. PEG-HDAd reduced IL-6 6-fold in mice and 3-fold in the primate. This vector reduced IL-12 by 50% in both animal models. PEGylation reduced serum transaminases by approximately 50% at each dose in the primate and the mouse. PEGylation did not alter hepatic transduction efficiency in the mouse but did reduce transduction efficiency in the liver and the spleen of primates. Unmodified and PEGylated virus suppressed hepatic CYP3A activity in both animal models. PEGylation doubled the half-life (t(½)) of the virus in the mouse and cut plasma clearance (CL) in half without affecting the half-life in primates. These results suggest that there are notable species-specific differences in the biodistribution of and response to PEG-modified vectors which may be linked to differences in binding properties to coagulation factors, receptor density and tissue architecture in the liver.
Wonganan
Piyanuch
P
Division of Pharmaceutics, College of Pharmacy, and Institute of Cellular and Molecular Biology, The University of Texas at Austin, Austin, Texas 78712, USA.
Clemens
Courtney C
CC
Brasky
Kathy
K
Pastore
Lucio
L
Croyle
Maria A
MA
D000256:Adenoviridae / Q000737:chemistry* / Q000378:metabolism*; D000818:Animals; D015139:Blotting, Southern; D015153:Blotting, Western; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D010215:Papio; D011092:Polyethylene Glycols / Q000737:chemistry*; D016133:Polymerase Chain Reaction; D014161:Transduction, Genetic
D011092:Polyethylene Glycols
Mol Ther. 2008 Jul;16(7):1276-82
18461056
Hum Gene Ther. 2007 Sep;18(9):837-48
17767399
J Biol Chem. 1977 Jun 10;252(11):3582-6
16907
Curr Opin Pulm Med. 2003 Mar;9(2):111-6
12574690
Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):871-7
18624676
J Virol Methods. 2008 Mar;148(1-2):132-45
18160141
Chest. 2002 Apr;121(4):1262-8
11948062
Gene Ther. 2005 Mar;12(5):427-36
15647774
J Gen Virol. 2000 Nov;81(Pt 11):2605-2609
11038370
Curr Gene Ther. 2008 Aug;8(4):222-35
18691018
Hum Gene Ther. 2003 Nov 20;14(17):1595-604
14633402
Expert Opin Drug Deliv. 2008 Apr;5(4):371-83
18426380
Mol Ther. 2004 Aug;10(2):344-54
15294181
J Biol Chem. 1977 Jun 10;252(11):3578-81
405385
Annu Rev Biomed Eng. 2008;10:169-94
18647114
J Pharm Sci. 2008 Oct;97(10):4167-83
18200508
Mol Ther. 2001 Jan;3(1):28-35
11162308
Hum Gene Ther. 2000 Aug 10;11(12):1713-22
10954905
Br J Haematol. 2003 Dec;123(5):903-5
14632782
Hum Gene Ther. 2002 Jan 1;13(1):143-54
11779418
Hum Gene Ther. 2008 Dec;19(12):1369-82
18778197
Int J Pharm. 2008 Apr 16;354(1-2):9-15
17640834
Curr Drug Saf. 2008 Jan;3(1):46-53
18690980
Pharmacogenet Genomics. 2010 Mar;20(3):167-78
20147837
Acad Emerg Med. 2008 Sep;15(9):795-9
19244629
Crit Rev Ther Drug Carrier Syst. 2008;25(5):403-47
19062633
N Engl J Med. 2001 May 17;344(20):1498-503
11357152
Gene Ther. 2005 Apr;12(7):579-87
15647765
Blood. 2007 Apr 1;109(7):2832-9
17148587
Curr Drug Metab. 2008 May;9(4):310-22
18473749
Virology. 1968 Sep;36(1):115-25
5669982
Gene Ther. 2003 Jun;10(12):1012-7
12776158
Methods Enzymol. 1978;52:109-17
672621
Hum Gene Ther. 2006 Apr;17(4):391-404
16610927
Pharmacogenet Genomics. 2008 Jan;18(1):53-66
18216722
Mol Genet Metab. 2003 Sep-Oct;80(1-2):148-58
14567964
Biotechnol Bioeng. 2005 Oct 5;92(1):24-34
15937953
Hum Gene Ther. 2003 May 20;14(8):777-87
12804140
Support Care Cancer. 2007 Mar;15(3):251-7
17139496
Hum Gene Ther. 2004 Jan;15(1):35-46
14965376
Virus Res. 2008 Mar;132(1-2):1-14
18036698
Pharm Dev Technol. 1998 Aug;3(3):373-83
9742558
Cancer Treat Rep. 1979 Jun;63(6):1127-32
466651
Br J Pharmacol. 2009 May;157(2):153-65
18776913
Int Rev Cytol. 1982;80:27-61
6295978
J Control Release. 2005 Nov 2;108(1):161-77
16125817
Am J Hum Genet. 1997 Sep;61(3):489-93
9326312
Mol Ther. 2007 Aug;15(8):1410-6
17505469
Expert Opin Drug Metab Toxicol. 2005 Dec;1(4):629-40
16863429
J Gene Med. 2006 May;8(5):566-76
16508909
Viruses. 2010 Feb;2(2):468-502
21994645
Hum Gene Ther. 2004 May;15(5):433-43
15144574
Methods Enzymol. 2002;346:177-98
11883068
Immunol Rev. 2001 Oct;183:127-40
11782253
Circulation. 2001 Mar 6;103(9):1274-81
11238273
BioDrugs. 2008;22(5):315-29
18778113
Drug Metab Dispos. 2008 Feb;36(2):205-16
18218849
Cell. 2008 Feb 8;132(3):397-409
18267072
Mol Ther. 2001 May;3(5 Pt 1):708-22
11356076
Mol Ther. 2005 Jan;11(1):66-79
15585407
Hum Gene Ther. 2002 Oct 10;13(15):1887-900
12396620
Virol J. 2008 Sep 30;5:111
18826641
J Pharmacol Exp Ther. 2005 Feb;312(2):492-501
15496614
Mol Ther. 2008 Jan;16(1):16-29
17912234
Am J Physiol. 1979 May;236(5):H775-9
443399
J Allergy Clin Immunol. 2006 Aug;118(2):295-302; quiz 303-4
16890750
P T. 2008 Nov;33(11):642-51
19750060
Gene Ther. 2008 Apr;15(8):553-60
18288209
Hum Gene Ther. 1999 Oct 10;10(15):2515-26
10543616
Methods Mol Biol. 2008;433:55-78
18679617
J Virol. 2001 May;75(10):4792-801
11312351
ILAR J. 2008;49(2):220-55
18323583
Anal Biochem. 1984 Apr;138(1):57-65
6731853
Br J Pharmacol. 2008 Aug;154(7):1382-99
18604233
Hum Gene Ther. 1999 May 20;10(8):1349-58
10365665
Curr Gene Ther. 2007 Oct;7(5):297-305
17979676
J Virol. 2004 Jan;78(2):912-21
14694122
Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5483-8
18391209
Cancer Gene Ther. 2002 Jul;9(7):553-66
12082455
Adv Drug Deliv Rev. 2003 Sep 26;55(10):1293-302
14499708